The treatment of these cancer cells with LXR agonists induced degradation of LDLR and increased apoptosis in glioblastoma cells expressing mutant epidermal growth factor receptor (EGFR), where tumor growth and survival is strongly dependent on SREBP-1-mediated lipogenesis (38). The gene discussed is EGFR; the disease is cancer.